Patients

New Standard in Melanoma May Save $1 Billion While Improving Lives

A new standard is poised to transform melanoma care in terms of both patient outcomes and economics. Results from the phase 3 NADINA trial (Abstract LBA2), presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, showed that a six-week course of neoadjuvant immunotherapy was superior to two years of adjuvant immunotherapy in treating macroscopic, resectable stage III melanoma.

Read More
MRV News
Melanoma News
Archive
Menu